Clinical trials: Lung Aspiration
Pulmonary Disease, Chronic Obstructive
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00115492
- Testing
- Fluticasone Propionate/Salmeterol Combination Product, Salmeterol
- Where
- 110 sites in United States, Canada
- Volunteers
- 797 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale.
- Trial name
- NCT00354666
- Testing
- GSK159797
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Asthma
Bronchodilator Properties and Safety in Asthma
Recent large clinical studies have demonstrated the interest of LAMA therapy in the management of asthma, when compared to LABA.
- Trial name
- NCT01951222
- Testing
- V0162
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Pierre Fabre Medicament
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to…
- Trial name
- NCT00961038
- Testing
- Ciprofloxacin (PulmoSphere, BAYQ3939)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease (COPD)
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.
- Trial name
- NCT01205269
- Testing
- AZD8683, 50 mcg, AZD8683, 200 mcg
- Where
- 4 sites in Poland
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
COPD
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The purpose of this study is to investigate the efficacy, safety and tolerability of 4 weeks treatment with AZD3199 in moderate to severe COPD.
- Trial name
- GLAD (NCT00929708)
- Testing
- AZD3199, formoterol
- Where
- 38 sites in Bulgaria, Canada and 3 more
- Volunteers
- 329 people
- Sponsor
- AstraZeneca
Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease(COPD)
A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to assess the long term safety and efficacy of AeriSeal System treatment administered at up to 4 subsegments during a single treatment session for lung volume reduction in patients with advanced…
- Conditions
- Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease(COPD), Lung Diseases
- Trial name
- NCT01320566
- Testing
- AeriSeal System
- Where
- 2 sites in Israel
- Volunteers
- 18 people
- Sponsor
- Aeris Therapeutics
Chronic Pulmonary Obstructive Disease, Emphysema
A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to provide post market clinical follow-up (PMCF) to obtain long term safety and efficacy information about the AeriSeal System treatment in patients with advanced emphysema.
- Trial name
- NCT01449175
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Aeris Therapeutics
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
AeriSeal System for Lung Volume Reduction
The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Emphysema, Lung Diseases
- Trial name
- NCT01051258
- Testing
- AeriSeal System
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Aeris Therapeutics
Disease, Pulmonary
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with mild to moderate COPD (stage I-II according to GOLD…
- Trial name
- NCT01052298
- Testing
- Ciprofloxacin (Cipro inhale, BAYQ3939)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis).
- Trial name
- NCT00741819
- Testing
- Inhaled treprostinil
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- United Therapeutics
COPD
AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending inhaled doses of AZD8683 in Healthy volunteers and repeated inhalation of one dose level of AZD8683 in patients…
- Trial name
- NCT01584739
- Testing
- AZD8683
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Emphysema, COPD
AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema
The purpose of this study is to assess the procedural and post-procedural safety and efficacy of AeriSeal therapy at up to 4 subsegments during a single treatment session in patients with GOLD Stage III/IV homogeneous or…
- Conditions
- Pulmonary Emphysema, COPD, Lung Diseases
- Trial name
- NCT01181466
- Testing
- AeriSeal System
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00801684
- Testing
- TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alkermes, Inc.
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition with deteriorating lung function over the years. Patients with COPD experience symptoms of shortness of breath, cough and sputum production.
- Trial name
- LaCrossE (NCT00939211)
- Testing
- AZD9164, Tiotropium
- Where
- 3 sites in Sweden
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension, Ayerza Syndrome
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
- Conditions
- Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
- Trial name
- NCT00086463
- Where
- 17 sites in United States
- Volunteers
- 60 people
- Sponsor
- Actelion
Chronic Obstructive Pulmonary Disease (COPD)
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.
- Trial name
- TOP (NCT00629239)
- Testing
- AZD4818
- Where
- 12 sites in Denmark, Finland and 3 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca